Table 4.
Treatments in the acute phase and outcomes at the end of follow-up in the FPCCVT and ISCVT cohorts.
| FPCCVT, | ISCVT, | p(X2) | |
|---|---|---|---|
| N = 231, | N = 624 | ||
| 21 centers in France | 89 centers in 21 countries | ||
| Number of cases (%) | Number of cases (%) | ||
| Treatments in acute phase | |||
| Heparin | |||
| UFH (IV + SC) | 140 (61) | 401 (64) | 0.32 |
| LMWH therapeutic dosage | 84 (36) | 218 (34.9) | 0.98 |
| LMWH prophylactic dosage | 1 (0.4) | 9 (1.4) | |
| Oral anticoagulant treatment | |||
| VKA | 1 (0.4) | ||
| DOAC | 4 (1.7) | ||
| Antiplatelet drugs | 5 (never alone) | 37 (5.9) | |
| No anticoagulant treatment | 2 (0.9) | ||
| Other treatments | |||
| External shunts | 2 (0.9) | 10 (1.6) | |
| Decompressive craniotomy | 2 (0.9) | 9 (1.4) | |
| Local thrombolysis | 0 | 13 (2.1) | |
| Additional treatments | |||
| Antalgic drugs | 199 (86.1) | ||
| Antiepileptics | 59 (25.5) | 277 (44.4) | <0.001 |
| Osmotherapy | 46 (19.9) | 82 (13.2) | 0.1 |
| Steroids | 19 (8.2) | 150 (24.1) | <0.001 |
| At the end of follow-up: | N = 205 | N = 564 | |
| Median duration = 11.9 months | Median duration = 16 months | ||
| Lost to follow-up | 26 (11.3) | 8 (1.3) | <0.001 |
| Median duration of anticoagulant treatment | 213 day | 231 days | |
| Recurrent CVT | 2 (1) | 14 (2.2) | 0.19 |
| Death | 8 (3.4) | 52 (8.3) | 0.01 |
| Rankin scale score | |||
| <2 | 181 (88.3) | 493 (87.4) | 0.46 |
| ≥2 | 24 (11.7) | 79 (14) | |
UFH, unfractioned heparin; LMWH, low molecular weight heparin; VKA, vitamin K antagonists; DOAC, direct oral anticoagulant. Bold p values are significant p values.